{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:02:58Z","timestamp":1789405378415,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021778","name":"Agencia Nacional de Promoci\u00f3n de la Investigaci\u00f3n, el Desarrollo Tecnol\u00f3gico y la Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FONARSEC PE PPM 2-L2B"],"award-info":[{"award-number":["FONARSEC PE PPM 2-L2B"]}],"id":[{"id":"10.13039\/501100021778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00284-024-03874-8","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T22:02:11Z","timestamp":1725400931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["New Highly Selective Antivirals for Chikungunya Virus identified from the Screening of a Drug-Like Compound Library"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1153-1176","authenticated-orcid":false,"given":"Eliana F.","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego E.","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"3874_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TMAID.2023.102603","author":"JD Grabenstein","year":"2023","unstructured":"Grabenstein JD, Tomar AS (2023) Global geotemporal distribution of chikungunya disease, 2011\u20132022. Travel Med Infect Dis. https:\/\/doi.org\/10.1016\/J.TMAID.2023.102603","journal-title":"Travel Med Infect Dis"},{"key":"3874_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1473-3099(07)70107-X","volume":"7","author":"G Pialoux","year":"2007","unstructured":"Pialoux G, Ga\u00fcz\u00e8re BA, Jaur\u00e9guiberry S, Strobel M (2007) Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 7:319\u2013327. https:\/\/doi.org\/10.1016\/S1473-3099(07)70107-X","journal-title":"Lancet Infect Dis"},{"key":"3874_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/J.TMAID.2013.07.006","volume":"11","author":"D Tomasello","year":"2013","unstructured":"Tomasello D, Schlagenhauf P (2013) Chikungunya and dengue autochthonous cases in Europe, 2007\u20132012. Travel Med Infect Dis 11:274\u2013284. https:\/\/doi.org\/10.1016\/J.TMAID.2013.07.006","journal-title":"Travel Med Infect Dis"},{"key":"3874_CR4","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(07)61779-6","volume":"370","author":"G Rezza","year":"2007","unstructured":"Rezza G, Nicoletti L, Angelini R et al (2007) Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370:1840\u20131846. https:\/\/doi.org\/10.1016\/S0140-6736(07)61779-6","journal-title":"Lancet"},{"key":"3874_CR5","doi-asserted-by":"publisher","first-page":"21108","DOI":"10.2807\/1560-7917.ES2015.20.17.21108\/CITE\/REFWORKS","volume":"20","author":"E Delisle","year":"2015","unstructured":"Delisle E, Rousseau C, Broche B et al (2015) Chikungunya outbreak in Montpellier, France, september to october 2014. Eurosurveillance 20:21108. https:\/\/doi.org\/10.2807\/1560-7917.ES2015.20.17.21108\/CITE\/REFWORKS","journal-title":"Eurosurveillance"},{"key":"3874_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(14)60185-9","volume":"383","author":"I Leparc-Goffart","year":"2014","unstructured":"Leparc-Goffart I, Nougairede A, Cassadou S et al (2014) Chikungunya in the Americas. Lancet 383:514. https:\/\/doi.org\/10.1016\/S0140-6736(14)60185-9","journal-title":"Lancet"},{"key":"3874_CR7","unstructured":"Pan American Health Organization \/ World Health Organization. Epidemiological Update: Chikungunya in the Region of the Americas. 22 April 2024. Washington, D.C. PAHO\/WHO; 2024"},{"key":"3874_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/J.LANA.2023.100673","volume":"30","author":"WM de Souza","year":"2024","unstructured":"de Souza WM, Ribeiro GS, de Lima STS et al (2024) Chikungunya: a decade of burden in the Americas. Lancet Reg Heal\u2014Am 30:100673. https:\/\/doi.org\/10.1016\/J.LANA.2023.100673","journal-title":"Lancet Reg Heal\u2014Am"},{"key":"3874_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANTIVIRAL.2019.104670","volume":"174","author":"L Pezzi","year":"2020","unstructured":"Pezzi L, Diallo M, Rosa-Freitas MG et al (2020) GloPID-R report on chikungunya, o\u2019nyong-nyong and Mayaro virus, part 5: entomological aspects. Antiviral Res 174:104670. https:\/\/doi.org\/10.1016\/J.ANTIVIRAL.2019.104670","journal-title":"Antiviral Res"},{"key":"3874_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0368-2315(06)76447-X","volume":"35","author":"Y Lenglet","year":"2006","unstructured":"Lenglet Y, Barau G, Robillard PY et al (2006) Infection \u00e0 Chikungunya chez la femme enceinte et risque de transmission materno-f\u0153tale: \u00c9tude dans un contexte d\u2019\u00e9pid\u00e9mie en 2005\u20132006 \u00e0 l\u2019\u00eele de la R\u00e9union. J Gyn\u00e9cologie Obs Biol la Reprod 35:578\u2013583. https:\/\/doi.org\/10.1016\/S0368-2315(06)76447-X","journal-title":"J Gyn\u00e9cologie Obs Biol la Reprod"},{"key":"3874_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3389\/FIMMU.2020.00695","volume":"11","author":"P Srivastava","year":"2020","unstructured":"Srivastava P, Kumar A, Hasan A et al (2020) Disease resolution in Chikungunya\u2014What decides the outcome? Front Immunol 11:695. https:\/\/doi.org\/10.3389\/FIMMU.2020.00695","journal-title":"Front Immunol"},{"key":"3874_CR12","doi-asserted-by":"publisher","unstructured":"Schneider M, Narciso-Abraham M, Hadl S, et al (2023) Articles Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. www.thelancet.com 401:. https:\/\/doi.org\/10.1016\/S0140-6736(23)00641-4","DOI":"10.1016\/S0140-6736(23)00641-4"},{"key":"3874_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/D41573-023-00201-X","author":"A Mullard","year":"2023","unstructured":"Mullard A (2023) FDA approves first chikungunya vaccine. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/D41573-023-00201-X","journal-title":"Nat Rev Drug Discov"},{"key":"3874_CR14","unstructured":"Kanaras J (2023) November 9, 2023 Approval Letter - IXCHIQ"},{"key":"3874_CR15","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","volume":"17","author":"FJ Burt","year":"2017","unstructured":"Burt FJ, Chen W, Miner JJ et al (2017) Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis 17:e107\u2013e117. https:\/\/doi.org\/10.1016\/S1473-3099(16)30385-1","journal-title":"Lancet Infect Dis"},{"key":"3874_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/V13071307","author":"V Battisti","year":"2021","unstructured":"Battisti V, Urban E, Langer T (2021) Antivirals against the chikungunya virus. Viruses. https:\/\/doi.org\/10.3390\/V13071307","journal-title":"Viruses"},{"key":"3874_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJBIOMAC.2024.129949","volume":"262","author":"M Wang","year":"2024","unstructured":"Wang M, Wang L, Leng P et al (2024) Drugs targeting structural and nonstructural proteins of the chikungunya virus: a review. Int J Biol Macromol 262:129949. https:\/\/doi.org\/10.1016\/J.IJBIOMAC.2024.129949","journal-title":"Int J Biol Macromol"},{"key":"3874_CR18","unstructured":"Medicines for Malaria Venture | Developing antimalarials to save lives. https:\/\/www.mmv.org\/. Accessed 2 Aug 2024"},{"key":"3874_CR19","unstructured":"DNDi \u2013 Best science for the most neglected. https:\/\/dndi.org\/. Accessed 2 Aug 2024"},{"key":"3874_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1021\/ACSINFECDIS.1C00527\/SUPPL_FILE\/ID1C00527_SI_002.XLSX","volume":"8","author":"K Samby","year":"2022","unstructured":"Samby K, Besson D, Dutta A et al (2022) The pandemic response box-accelerating drug discovery efforts after disease outbreaks. ACS Infect Dis 8:713\u2013720. https:\/\/doi.org\/10.1021\/ACSINFECDIS.1C00527\/SUPPL_FILE\/ID1C00527_SI_002.XLSX","journal-title":"ACS Infect Dis"},{"key":"3874_CR21","unstructured":"Pandemic Response Box | DNDi. https:\/\/dndi.org\/research-development\/portfolio\/pandemic-response-box\/. Accessed 2 Aug 2024"},{"key":"3874_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/V14071351","author":"LR Policastro","year":"2022","unstructured":"Policastro LR, Dolci I, Godoy AS et al (2022) The antifungal itraconazole is a potent inhibitor of chikungunya virus replication. Viruses. https:\/\/doi.org\/10.3390\/V14071351","journal-title":"Viruses"},{"key":"3874_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/J.CELREP.2019.06.022","volume":"28","author":"MG Noval","year":"2019","unstructured":"Noval MG, Rodriguez-Rodriguez BA, Rangel MV, Stapleford KA (2019) Evolution-driven attenuation of alphaviruses highlights key glycoprotein determinants regulating viral infectivity and dissemination. Cell Rep 28:460. https:\/\/doi.org\/10.1016\/J.CELREP.2019.06.022","journal-title":"Cell Rep"},{"key":"3874_CR24","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1021\/ACSINFECDIS.0C00915","volume":"7","author":"L Battini","year":"2021","unstructured":"Battini L, Fidalgo DM, \u00c1lvarez DE, Bollini M (2021) Discovery of a potent and selective chikungunya virus envelope protein inhibitor through computer-aided drug design. ACS Infect Dis 7:1503\u20131518. https:\/\/doi.org\/10.1021\/ACSINFECDIS.0C00915","journal-title":"ACS Infect Dis"},{"key":"3874_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/FPUBH.2020.618624","volume":"8","author":"FIL Hucke","year":"2020","unstructured":"Hucke FIL, Bugert JJ (2020) Current and promising antivirals against chikungunya virus. Front Public Heal 8:618624. https:\/\/doi.org\/10.3389\/FPUBH.2020.618624","journal-title":"Front Public Heal"},{"key":"3874_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.antiviral.2017.10.010","volume":"149","author":"MJ Pascual","year":"2018","unstructured":"Pascual MJ, Merwaiss F, Leal E et al (2018) Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry. Antiviral Res 149:179\u2013190. https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.010","journal-title":"Antiviral Res"},{"key":"3874_CR27","doi-asserted-by":"publisher","DOI":"10.5772\/INTECHOPEN.71923","author":"\u00d6S Aslant\u00fcrk","year":"2017","unstructured":"Aslant\u00fcrk \u00d6S, Aslant\u00fcrk \u00d6S (2017) In vitro cytotoxicity and cell viability assays: principles, advantages, and disadvantages. Genotoxicity\u2014A predict risk to our actual world. https:\/\/doi.org\/10.5772\/INTECHOPEN.71923","journal-title":"Genotoxicity\u2014A predict risk to our actual world"},{"key":"3874_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/JMV.21663","volume":"82","author":"M Khan","year":"2010","unstructured":"Khan M, Santhosh SR, Tiwari M et al (2010) Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells. J Med Virol 82:817. https:\/\/doi.org\/10.1002\/JMV.21663","journal-title":"J Med Virol"},{"key":"3874_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.ANTIVIRAL.2008.12.015","volume":"82","author":"R Harvey","year":"2009","unstructured":"Harvey R, Brown K, Zhang Q et al (2009) GSK983: a novel compound with broad-spectrum antiviral activity. Antiviral Res 82:1. https:\/\/doi.org\/10.1016\/J.ANTIVIRAL.2008.12.015","journal-title":"Antiviral Res"},{"key":"3874_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/J.CHEMBIOL.2020.05.002","volume":"27","author":"Q Liu","year":"2020","unstructured":"Liu Q, Gupta A, Okesli-Armlovich A et al (2020) Enhancing the antiviral efficacy of RNA-dependent RNA polymerase inhibition by combination with modulators of pyrimidine metabolism. Cell Chem Biol 27:668-677.e9. https:\/\/doi.org\/10.1016\/J.CHEMBIOL.2020.05.002","journal-title":"Cell Chem Biol"},{"key":"3874_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/J.CHEMBIOL.2006.02.007","volume":"13","author":"H Tang","year":"2006","unstructured":"Tang H, Doerksen RJ, Jones TV et al (2006) Biomimetic facially amphiphilic antibacterial oligomers with conformationally stiff backbones. Chem Biol 13:427\u2013435. https:\/\/doi.org\/10.1016\/J.CHEMBIOL.2006.02.007","journal-title":"Chem Biol"},{"key":"3874_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/V13020271","author":"A Bakovic","year":"2021","unstructured":"Bakovic A, Risner K, Bhalla N et al (2021) Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses. https:\/\/doi.org\/10.3390\/V13020271","journal-title":"Viruses"},{"key":"3874_CR33","first-page":"1","volume":"18","author":"C Xu","year":"2022","unstructured":"Xu C, Wang A, Honnen W et al (2022) Brilacidin, a non-peptide defensin-mimetic molecule, inhibits SARS-CoV-2 infection by blocking viral entry. EC Microbiol 18:1","journal-title":"EC Microbiol"},{"key":"3874_CR34","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/JMV.27616","volume":"94","author":"Y Hu","year":"2022","unstructured":"Hu Y, Jo H, DeGrado WF, Wang J (2022) Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. J Med Virol 94:2188. https:\/\/doi.org\/10.1002\/JMV.27616","journal-title":"J Med Virol"},{"key":"3874_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/MICROORGANISMS12010054\/S1","author":"CA Anderson","year":"2024","unstructured":"Anderson CA, Barrera MD, Boghdeh NA et al (2024) Brilacidin as a broad-spectrum inhibitor of enveloped, acutely infectious viruses. Microorganisms. https:\/\/doi.org\/10.3390\/MICROORGANISMS12010054\/S1","journal-title":"Microorganisms"},{"key":"3874_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES28237874","author":"W Hou","year":"2023","unstructured":"Hou W, Huang LJ, Huang H et al (2023) Bioactivities and mechanisms of action of diphyllin and its derivatives: a comprehensive systematic review. Mol. https:\/\/doi.org\/10.3390\/MOLECULES28237874","journal-title":"Mol"},{"key":"3874_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9030471","author":"M Stefanik","year":"2021","unstructured":"Stefanik M, Strakova P, Haviernik J et al (2021) Microorganisms antiviral activity of vacuolar ATPase blocker diphyllin against SARS-CoV-2. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms9030471","journal-title":"Microorganisms"},{"key":"3874_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/J.ANTIVIRAL.2013.06.014","volume":"99","author":"HW Chen","year":"2013","unstructured":"Chen HW, Cheng JX, Liu MT et al (2013) Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antiviral Res 99:371. https:\/\/doi.org\/10.1016\/J.ANTIVIRAL.2013.06.014","journal-title":"Antiviral Res"},{"key":"3874_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1055\/S-2006-962087\/BIB","volume":"55","author":"WD MacRae","year":"1989","unstructured":"MacRae WD, Hudson JB, Towers GHN (1989) The antiviral action of lignans. Planta Med 55:531\u2013535. https:\/\/doi.org\/10.1055\/S-2006-962087\/BIB","journal-title":"Planta Med"},{"key":"3874_CR40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S1875-5364(19)30117-7","volume":"17","author":"XY Xu","year":"2019","unstructured":"Xu XY, Wang DY, Ku CF et al (2019) Anti-HIV lignans from Justicia procumbens. Chin J Nat Med 17:945\u2013952. https:\/\/doi.org\/10.1016\/S1875-5364(19)30117-7","journal-title":"Chin J Nat Med"},{"key":"3874_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/SPECTRUM.02351-23","author":"AJK Coyne","year":"2024","unstructured":"Coyne AJK, Alosaimy S, Lucas K et al (2024) Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. https:\/\/doi.org\/10.1128\/SPECTRUM.02351-23","journal-title":"Microbiol Spectr"},{"key":"3874_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23126468\/S1","author":"S Jo","year":"2022","unstructured":"Jo S, Signorile L, Kim S et al (2022) A study of drug repurposing to identify SARS-CoV-2 main protease (3CLpro) inhibitors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS23126468\/S1","journal-title":"Int J Mol Sci"},{"key":"3874_CR43","doi-asserted-by":"publisher","first-page":"14570","DOI":"10.1038\/S41598-023-41820-Z","volume":"13","author":"TA Alandijany","year":"2023","unstructured":"Alandijany TA, El-Daly MM, Tolah AM et al (2023) A multi-targeted computational drug discovery approach for repurposing tetracyclines against monkeypox virus. Sci Rep 13:14570. https:\/\/doi.org\/10.1038\/S41598-023-41820-Z","journal-title":"Sci Rep"},{"key":"3874_CR44","unstructured":"Epa U, of Pesticide Programs O (2007) US EPA - Pesticides - Fact Sheet for Fluopicolide"},{"key":"3874_CR45","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1021\/ACS.JAFC.3C08485\/SUPPL_FILE\/JF3C08485_SI_001.PDF","volume":"72","author":"T Dai","year":"2024","unstructured":"Dai T, Yang J, Zhao C et al (2024) Unveiling vacuolar H+-ATPase subunit a as the primary target of the pyridinylmethyl-benzamide fungicide, fluopicolide. J Agric Food Chem 72:1527\u20131538. https:\/\/doi.org\/10.1021\/ACS.JAFC.3C08485\/SUPPL_FILE\/JF3C08485_SI_001.PDF","journal-title":"J Agric Food Chem"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-024-03874-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-024-03874-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-024-03874-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:05:32Z","timestamp":1726661132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-024-03874-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3874"],"URL":"https:\/\/doi.org\/10.1007\/s00284-024-03874-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.17.594707","asserted-by":"object"}]},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EFC and DEA declare no competing interests relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"343"}}